13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • DAIICHI

    Acronym: 

    DAIICHI

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Breast
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2- antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1

    Lay Summary

    Sponsor / Cooperative group

    Daiichi

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Not Yet Recruiting